Unlock KRAS G12C for lung cancer treatment decisions
Oncology │ KRAS

Unlock KRAS G12C for lung cancer treatment decisions

KRAS G12C – the key to a new treatment option

The therascreen KRAS RGQ PCR Kit is an FDA-approved companion diagnostic (CDx) test to identify NSCLC patients that may be eligible for treatment with LUMAKRAS (soratasib) or KRAZATI (adagrasib), based on the detection of KRAS G12C mutation.

Reliably detect the KRAS mutation that matters

The therascreen KRAS RGQ PCR Kit is a unique molecular test, based on the detection of specific KRAS mutations in tumor DNA isolated from formalin-fixed paraffin-embedded (FFPE) NSCLC tumor tissue. The kit targets seven mutations in codons 12 and 13 of the KRAS gene (G12A, G12D, G12R, G12C, G12S, G12V and G13D).

Get the details
Reliably detect the KRAS mutation that matters
Start testing for KRAS G12C
Start testing for KRAS G12C

Find a laboratory offering testing using the therascreen KRAS RGQ PCR Kit to start making informed NSCLC treatment decisions.

Find a lab
Solutions for precision healthcare

QIAGEN’s therascreen kits allow you to access relevant genomic information for each patient and use it to make the best treatment decisions possible.

Browse our products
Solutions for precision healthcare
The therascreen KRAS RGQ PCR Kit is intended for in vitro diagnostic use.